Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
BörsenkürzelPRPO
Name des UnternehmensPrecipio Inc
IPO-datumJul 18, 2000
CEODanieli (Ilan S)
Anzahl der mitarbeiter54
WertpapierartOrdinary Share
GeschäftsjahresendeJul 18
Addresse4 Science Park
StadtNEW HAVEN
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl06511
Telefon12037877888
Websitehttps://www.precipiodx.com/
BörsenkürzelPRPO
IPO-datumJul 18, 2000
CEODanieli (Ilan S)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten